Introduction
COVID-19, a coronavirus infection caused by SARS-CoV-2, has put a strain on healthcare systems. The infection spreads quickly, and the lack of universal testing and personal protective equipment have aggravated the situation, as has the prevalence of silent infections. Because of the vast number of COVID 19-infected individuals who present to various hospitals, a thorough understanding of the clinical, radiographic, and laboratory findings connected to higher severity of disease severity and death is required. The identification of potential risk factors for illness progression could be immensely valuable for healthcare personnel in triaging patients, customizing treatment, monitoring clinical progress, and allocating sufficient support at all levels to prevent disease progress and death (1,2).
The SARS-CoV-2 characteristic of primary dormancy signs is another element leading to the fast prevalence and dangerously large number of affected patients. Fever with a quick start, coughing, and dyspnea are the most prevalent symptoms of COVID-19. Pneumonia, renal failure, bacterial superinfections, coagulation problems, and thrombosis are complications. Several clinical and demographic variables, such as advanced age, cardiovascular disease, and diabetes, are associated with poor outcomes and higher risks of mortality. In more vulnerable patients, such as infants, children, the elderly, and pregnant women, this knowledge gap has an impact on infection risk, illness progression, and outcomes. It is critical to understand better the risks of these vulnerable patients to improve and personalize their treatment and prevention techniques (2,3).
In terms of the extent of precautions and limits adopted by countries, COVID-19 mortality and morbidity rates differ substantially. The epidemiology of COVID-19 is substantially variable due to socio-cultural or lifestyle disparities among residents, as well as disparities in-country health policy. As a result, the fundamental causes of the severe pandemic outbreak need to be elucidated and we aimed to investigate the impacts of demographic, hematological, and biochemical factors on the clinical course and the prognostic outcome in adult COVID-19 patients.